Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy

Oncology (Switzerland)

Volumn 85, Issue 1, 2013, Pages 8-13

  Maj Hes, Agnes ^a,c   Medioni, Jacques ^c   Scotte, Florian ^c   Schmidinger, Manuela ^b   Kramer, Gero ^b   Combe, Pierre ^c   Gornadha, Yohan ^c   Elaidi, Reza ^c   Oudard, Stéphane ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Urologische Universitatsklinik   (Austria)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Everolimus; Mammalian target of rapamycin inhibitor rechallenge; Metastatic renal cell carcinoma; Sequential targeted therapy; Sunitinib rechallenge; Temsirolimus

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER PATIENT; CANCER STAGING; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; ANEMIA; ANOREXIA; ASTHENIA; BONE METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; DIARRHEA; DRUG EFFICACY; DRUG RECHALLENGE; EDEMA; FEASIBILITY STUDY; HYPERGLYCEMIA; IMAGE ANALYSIS; KIDNEY FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; PNEUMONIA; RETROSPECTIVE STUDY; SKIN INFECTION;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84879133944     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000350005     Document Type: Article

References (24)

1. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
2. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
3. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
4. Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287.
5. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-6422.
6. Corradetti MN, Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006; 25: 6347-6360.
7. Benjamin D, Colombi M, Moroni C, Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-880.
8. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
10. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA: Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012; 48: 333-339.
11. Gruenwald V, Seidel C, Busch J, Fenner M, Weikert S: Second-line everolimus treatment is effective in RCC patients with poor progression-free survival (PFS) in first-line VEGF-targeted therapies. J Clin Oncol 2011; 29(suppl): abstract e15028.
12. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
13. Oudard S, Elaidi RT: Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 2012; 38: 981-987.
14. Grunwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M: Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 2011; 34: 310-314.
15. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V: Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010; 58: 906-911.
16. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI: Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116: 5400-5406.
17. Oudard S: More than 4 years of progressionfree survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res 2010; 30: 5223-5225.
18. Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H, Ravaud A: Efficacy of rechallenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol 2011; 50: 1135-1136.
19. Wysocki PJ: mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009; 9: 231-241.
20. Hudes GR: Targeting mTOR in renal cell carcinoma. Cancer 2009; 115: 2313-2320.
21. Dancey JE: Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5: 1065-1073.
22. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J: Doseand schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
23. Escudier B: New therapies after failure of angiogenesis inhibitors. Clin Adv Hematol Oncol 2009; 7: 512-514.
24. Voss MH, Molina AM, Motzer RJ: mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 835-852.